Circulating ” Cancer Cells / Macrophage ” HYbrid Cells in Patients With Sarcoma, Part 2

Learn more about:
Related Clinical Trial
Circulating ” Cancer Cells / Macrophage ” HYbrid Cells in Patients With Sarcoma, Part 2 A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma Targeting ATR in Soft-tissue Sarcomas CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma S9624 Ifosfamide in Treating Patients With Meningeal Tumors A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Concordance Between Gynaecologic Sonography Amd Pelvic MRI for the Pre-surgical Diagnosis of Uterine Mesenchimal Malignant Tumors A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

Brief Title

Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2

Official Title

Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2

Brief Summary

      Pilot, prospective, monocentric study aimed at evaluating the rate of patients with
      circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution
      of this rate over time.

      The study will be conducted on a population of patients with leiomyosarcoma and treated in
      the context of routine care. 20 patients will be included:

        -  10 patients with localized disease.

        -  10 patients with metastatic disease.

      For each included patient, blood samples will be collected during baseline visit and up to 24
      months after inclusion.
    



Study Type

Interventional


Primary Outcome

The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.

Secondary Outcome

 Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.

Condition

Leiomyosarcoma

Intervention

Blood samples will be collected at different times.

Study Arms / Comparison Groups

 Patient with leiomyosarcoma
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

20

Start Date

October 2022

Completion Date

July 2026

Primary Completion Date

July 2026

Eligibility Criteria

        Inclusion Criteria:

          1. Patient with leiomyosarcoma.

          2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de
             Référence en Pathologie des Sarcomes et des Viscères)

          3. Localized or metastatic disease

          4. Newly diagnosed patient who has not yet initiated specific treatment for sarcoma

          5. Age ≥ 18 years

          6. Patient affiliated to a Social Security system in France.

          7. Patient having signed informed consent prior to inclusion in the study and prior to
             any specific study procedures

        Exclusion Criteria:

          1. Diagnosis of any other histological subtype of soft tissue sarcoma

          2. Associated pathology(ies) that may interfere with the study procedure

          3. Pregnant or breastfeeding woman

          4. Any psychological, family, geographical or sociological condition that does not allow
             for compliance with the medical follow-up and/or procedures provided for in the study
             protocol.

          5. Patient who has forfeited his/her freedom by administrative or legal award or who is
             under legal protection (curatorship and guardianship, protection of justice).
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, 05 31 15 51 70, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT05427461

Organization ID

22 SARC 03


Responsible Party

Sponsor

Study Sponsor

Institut Claudius Regaud

Collaborators

 Fondation ARC

Study Sponsor

, , 


Verification Date

August 2022